Ziextenzo 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
N/0031 
Minor change in labelling or package leaflet not 
30/11/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0028 
C.I.z - Changes (Safety/Efficacy) of Human and 
18/08/2023 
Veterinary Medicinal Products - Other variation 
SmPC, Annex 
II, Labelling 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
IAIN/0029/G 
This was an application for a group of variations. 
11/08/2023 
and PL 
Annex II and 
PL 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
Page 2/9 
 
 
 
 
 
 
 
 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IA/0027 
A.7 - Administrative change - Deletion of 
10/07/2023 
n/a 
manufacturing sites 
R/0025 
Renewal of the marketing authorisation. 
26/04/2023 
23/06/2023 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Ziextenzo in the approved indication remains favourable 
and therefore recommended the renewal of the marketing 
authorisation with unlimited validity. 
IB/0026/G 
This was an application for a group of variations. 
16/05/2023 
n/a 
B.II.b.1.z - Replacement or addition of a 
manufacturing site for the FP - Other variation 
B.II.b.1.z - Replacement or addition of a 
manufacturing site for the FP - Other variation 
B.II.b.1.z - Replacement or addition of a 
manufacturing site for the FP - Other variation 
B.II.e.3.b - Change in test procedure for the 
immediate packaging of the finished product - Other 
changes to a test procedure (including replacement 
or addition) 
B.II.b.1.z - Replacement or addition of a 
manufacturing site for the FP - Other variation 
B.II.b.1.z - Replacement or addition of a 
manufacturing site for the FP - Other variation 
Page 3/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0024 
B.II.d.2.a - Change in test procedure for the finished 
02/12/2022 
n/a 
product - Minor changes to an approved test 
procedure 
IA/0023 
B.II.c.2.a - Change in test procedure for an excipient 
20/10/2022 
n/a 
- Minor changes to an approved test procedure 
PSUSA/2326/
Periodic Safety Update EU Single assessment - 
29/09/2022 
n/a 
PRAC Recommendation - maintenance 
202201 
pegfilgrastim 
IB/0022 
B.I.a.1.f - Change in the manufacturer of AS or of a 
08/09/2022 
n/a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
IB/0021 
B.I.e.5.c - Implementation of changes foreseen in an 
08/08/2022 
n/a 
approved change management protocol - For a 
biological/immunological medicinal product 
II/0019 
B.II.e.1.b.2 - Change in immediate packaging of the 
10/06/2022 
23/06/2023 
SmPC and PL 
Section 6.5 “Nature and contents of container” of the SmPC 
finished product - Change in type/addition of a new 
container - Sterile medicinal products and 
biological/immunological medicinal products 
is updated to identify the material of the plunger stopper 
and rubber needle cap and to inform about the gauge of 
the needle. 
The Package Leaflet (PL) is updated accordingly in section 6 
“Contents of the pack and other information. 
The Instruction for Use was also supplemented with more 
precise information (Important safety information, 
Preparing the Ziextenzo pre filled syringe ready for use, 
How to use the Ziextenzo pre filled syringe). 
Page 4/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0018 
B.I.b.2.a - Change in test procedure for AS or 
09/02/2022 
n/a 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
IB/0017 
B.I.a.2.a - Changes in the manufacturing process of 
10/11/2021 
n/a 
the AS - Minor change in the manufacturing process 
of the AS 
II/0014 
B.I.e.2 - Introduction of a post approval change 
02/09/2021 
n/a 
management protocol related to the AS 
IB/0016 
C.I.2.a - Change in the SPC, Labelling or PL of a 
07/07/2021 
05/05/2022 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
IA/0015 
B.I.b.2.a - Change in test procedure for AS or 
08/06/2021 
n/a 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
IB/0013 
C.I.2.a - Change in the SPC, Labelling or PL of a 
22/04/2021 
05/05/2022 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
IA/0012 
A.4 - Administrative change - Change in the name 
18/09/2020 
n/a 
and/or address of a manufacturer or an ASMF holder 
Page 5/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
IA/0011 
B.I.b.2.a - Change in test procedure for AS or 
31/07/2020 
n/a 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
IB/0010/G 
This was an application for a group of variations. 
26/06/2020 
n/a 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
IB/0009 
B.I.a.1.k - Change in the manufacturer of AS or of a 
24/06/2020 
n/a 
starting material/reagent/intermediate for AS - New 
storage site of MCB and/or WCB 
IA/0008 
B.II.e.6.b - Change in any part of the (primary) 
05/06/2020 
n/a 
packaging material not in contact with the finished 
product formulation - Change that does not affect 
the product information 
IB/0007 
B.I.a.2.a - Changes in the manufacturing process of 
14/05/2020 
n/a 
the AS - Minor change in the manufacturing process 
of the AS 
Page 6/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II/0005/G 
This was an application for a group of variations. 
02/04/2020 
n/a 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.a.2.b - Changes in the manufacturing process of 
the AS - Substantial change to the manufacturing 
process of the AS which may have a significant 
impact on the quality, safety or efficacy of the 
medicinal product 
B.I.a.3.e - Change in batch size (including batch size 
ranges) of AS or intermediate - The scale for a 
biological/immunological AS is increased/decreased 
without process change (e.g. duplication of line) 
II/0004 
B.I.b.1.g - Change in the specification parameters 
19/03/2020 
n/a 
and/or limits of an AS, starting 
material/intermediate/reagent - Widening of the 
approved specs for starting mat./intermediates, 
which may have a significant effect on the quality of 
the AS and/or the FP 
IB/0006 
B.II.f.1.d - Stability of FP - Change in storage 
07/01/2020 
17/12/2020 
SmPC and PL 
conditions of the finished product or the 
diluted/reconstituted product 
PSUSA/2326/
Periodic Safety Update EU Single assessment - 
19/09/2019 
28/11/2019 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
201901 
pegfilgrastim 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/2326/201901. 
Page 7/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0003/G 
This was an application for a group of variations. 
29/07/2019 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IB/0002/G 
This was an application for a group of variations. 
04/07/2019 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
Page 8/9 
 
 
 
 
 
 
 
 
 
 
 
 
Page 9/9 
 
 
 
 
 
 
 
